DEM BioPharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DEM BioPharma, Inc. - overview
Established
2022
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
In 2022, the company was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik. In the year of its establishment, USD 17. 5 million was raised from venture funding co-led by new investors Alta Partners and Longwood Fund, with participation from other new investors Alexandria Venture Investments, Astellas Venture Management, Emerson Collective, Insight Partners, Pfizer Venture Investments, and UTokyo Innovation Platform.
The company runs a platform called CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) can be used to explore new DEM and EM signals via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. The company plans to use proceeds from its venture capital raised in 2022 to further develop its platform and to advance its portfolio of novel targets towards therapeutic development in oncology.
Current Investors
Alta Partners, Insight Partners, Alexandria Venture Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.dembiopharma.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.